AgingResearch.NewsJoin free

Calcilytix Therapeutics

Part of BridgeBio

CompanyUnited States

Calcilytix Therapeutics develops one asset, in phase 3 (Encaleret in autosomal dominant hypocalcemia). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Phase 3
1
Trial
0
Signals

Pipeline

1

  • Encaleret

    Negative allosteric modulator (calcilytic) of the calcium-sensing receptor.

    Phase 3, Small molecule, autosomal dominant hypocalcemia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals2
  • Similar companies1

Intelligence